References in the content below refer to the PBMEF Guide.
Definitions
Percent of drug-resistant (DR) TB patients (rifampicin-resistant [RR] and multidrug-resistant [MDR] TB and pre-extensively drug-resistant [pre-XDR] and extensively drug-resistant [XDR] TB) who received nonmedical interventions or benefits, aimed at improving treatment adherence and reduction of catastrophic cost during a specified period, among people with DR-TB who were initiated on treatment during the reporting period. This may include adherence support; food assistance; psychological, educational, or mental counseling; transportation reimbursement; or other social or economic support.
Numerator
Denominator
Ref # |
TX_DR_SUPPORT
(Previously RS-7) |
Tier Level |
Project Level Indicators
|
Category |
Cure
|
Type |
Output
|
Unit of Measure |
Percent of people
|
Data Type |
Percentage
|
Disaggregations |
Age (<15, 15+)
Sex
|
Reporting Level |
National and subnational
|
Reporting Frequency |
Annually, quarterly, monthly
|
The data sources for this indicator may vary country to country but will likely be found in a national or centralized registry for social support. Also, depending on whether TB support packages are rolled out nationwide or only through nongovernmental organizations (NGOs) or community organizations, this data could also be found in records kept by implementing partners (IPs).
Treatment support for people on DR-TB treatment is essential to ensure successful outcomes. Support packages may include adherence support; food assistance; psychological, educational, or mental counseling; transportation reimbursement; or other social or economic support to people on DR-TB treatment. Support packages help to ensure that people on treatment have access to key nutritional assistance which can lead to better treatment outcomes; additionally, these packages work to minimize or prevent the catastrophic costs that can be associated with DR-TB.
These associated costs can include the transport needed to get to and from the health facility; healthcare costs such as visit fees, medicine fees, or testing fees; and the loss of income due to illness or missing work in order to access the necessary care. Catastrophic costs incurred by people diagnosed with DR-TB can negatively affect their treatment and lead to long-term financial hardship even after successful DR-TB treatment. This is particularly important given the long duration of DR-TB treatment.
This indicator works to measure efforts being undertaken by countries to minimize or prevent the catastrophic costs associated with DR-TB. Understanding the percent of people on DR-TB treatment who have received these support packages demonstrate the reach of these support services and can highlight existing gaps.
The percent of people on DR-TB treatment who have received support packages can help countries monitor the reach of these support programs. When disaggregated, this indicator can help highlight differences or gaps in the distribution or utilization of these support services by multiple factors including reach in specific geographies, across specific populations, particularly high-risk groups, and between genders. Understanding who is and who is not receiving TB support packages can help National TB Programs (NTPs) identify populations or groups that need additional coverage and target their resources accordingly.
For data visualizations, the percentage of DR-TB patients receiving TB support packages can be plotted over time for a particular country or regions. These visuals could also show important disaggregations such as gender.
Example charts/graphs:
- Graph of percent of DR-TB patients receiving TB support packages over time for each region of a given country
- Graph of percent of DR-TB patients receiving TB support packages over time disaggregated by gender (stacked bar graph)
Indicator Visualizations
We do not currently have an indicator visualization for this indicator. Please check back later.